Special Issue

Targeting Opioid Receptors for Innovative Therapies: Present and Emerging Concepts in Opioid Cure

Message from the Guest Editors

In today's medicine, opioids are most often used to relieve pain, both acute (e.g., postoperative) and chronic. Apart from that, pharmacological agents that alter the opioid system's activity are commonly used for the treatment of alcohol dependence (e.g., naltrexone). The undoubtful role of the opioid system in neurodegenerative diseases (e.g., Parkinson's or Alzheimer's disease), cardiovascular diseases, or cancer development has been widely discussed in the scientific literature, which resulted in the description of new molecular mechanisms, ultimately leading to the development of new pharmacotherapies.

Due to the overall importance of the opioid system, authors are invited to submit original and review articles to contribute to the understanding of the current state of the opioid receptors as potential therapeutic targets, as well as describe the new role of these receptors in various diseases, to be published in this Special Issue of Pharmaceuticals. The proposed topics cover therapy for pain, addiction, neurodegenerative diseases, cardiovascular diseases, and cancer.

Guest Editors

Dr. Piotr Poznanski

Dr. Marzena Łazarczyk

Dr. Dominik Skiba

Deadline for manuscript submissions

closed (25 May 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/195509

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

